PE20181516A1 - Medicamento para tratar la gripe caracterizado por combinar un inhibidor de endonucleasa dependiente de cap y un farmaco antigripal - Google Patents

Medicamento para tratar la gripe caracterizado por combinar un inhibidor de endonucleasa dependiente de cap y un farmaco antigripal

Info

Publication number
PE20181516A1
PE20181516A1 PE2018001110A PE2018001110A PE20181516A1 PE 20181516 A1 PE20181516 A1 PE 20181516A1 PE 2018001110 A PE2018001110 A PE 2018001110A PE 2018001110 A PE2018001110 A PE 2018001110A PE 20181516 A1 PE20181516 A1 PE 20181516A1
Authority
PE
Peru
Prior art keywords
flu
medication
cap
combining
drug
Prior art date
Application number
PE2018001110A
Other languages
English (en)
Inventor
Takao Shishidojp
Takeshi Noshi
Atsuko Yamamoto
Mitsutaka Kitano
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PE20181516A1 publication Critical patent/PE20181516A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Se refiere a un medicamento caracterizado porque (A) un compuesto representado por la formula (I): su sal farmaceuticamente aceptable, o un solvato del mismo, en la que P es H o un grupo para formar un profarmaco; A1 es CR1AR1B, S u O; A2 es CR2AR2B, S u O; A3 es CR3AR3B, S u O; A4 es CR4AR4B, S u O; el numero de heteroatomos entre los atomos que constituyen el anillo que consiste en A1, A2, A3, A4, atomo de nitrogeno adyacente a A1 y atomo de carbono adyacente A4 es 1 o 2; R1A, R1B, R2A, R2B, R3A, R3B, R4A y R4B son H, halogeno, alquilo, entre otros; son H, halogeno, alquilo, entre otros; son H, halogeno, alquilo, entre otros; n es cualquier numero entero de 1 a 2 y R1 es un compuesto de formula (II), se combina con (B) compuestos que tienen una actividad antigripal.
PE2018001110A 2015-12-15 2016-12-14 Medicamento para tratar la gripe caracterizado por combinar un inhibidor de endonucleasa dependiente de cap y un farmaco antigripal PE20181516A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015244492 2015-12-15

Publications (1)

Publication Number Publication Date
PE20181516A1 true PE20181516A1 (es) 2018-09-21

Family

ID=59057323

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001110A PE20181516A1 (es) 2015-12-15 2016-12-14 Medicamento para tratar la gripe caracterizado por combinar un inhibidor de endonucleasa dependiente de cap y un farmaco antigripal

Country Status (19)

Country Link
US (1) US11040048B2 (es)
EP (1) EP3391888B1 (es)
JP (1) JP6323860B2 (es)
KR (1) KR102084109B1 (es)
CN (1) CN108697715A (es)
AU (1) AU2016374416A1 (es)
BR (1) BR112018011103A2 (es)
CA (1) CA3008607A1 (es)
CL (1) CL2018001618A1 (es)
CR (1) CR20180356A (es)
HK (1) HK1254961A1 (es)
IL (1) IL260025A (es)
MA (1) MA44080A (es)
MX (1) MX2018006966A (es)
PE (1) PE20181516A1 (es)
RU (1) RU2745071C2 (es)
SG (2) SG11201804348SA (es)
WO (1) WO2017104691A1 (es)
ZA (1) ZA201803246B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2983721A1 (en) 2015-04-24 2016-10-27 Shionogi & Co., Ltd. 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same
PL3428170T3 (pl) * 2015-04-28 2021-05-31 Shionogi & Co., Ltd Pochodna policyklicznego pirydonu o działaniu przeciwgrypowym i jej prolek
JP5971830B1 (ja) * 2015-04-28 2016-08-17 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグ
MX2018016267A (es) 2016-06-20 2019-05-20 Shionogi & Co Metodo para producir derivado de piridona policiclica sustituida y cristal del mismo.
CA3033180C (en) 2016-08-10 2022-05-31 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
TWI785116B (zh) * 2017-09-18 2022-12-01 大陸商廣東東陽光藥業有限公司 流感病毒複製抑制劑及其用途
WO2019070059A1 (ja) * 2017-10-06 2019-04-11 塩野義製薬株式会社 置換された多環性ピリドン誘導体の立体選択的な製造方法
TWI795462B (zh) * 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
CN110041327B (zh) * 2018-01-17 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN111303147A (zh) * 2018-12-12 2020-06-19 银杏树药业(苏州)有限公司 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
JP7352297B2 (ja) * 2018-01-17 2023-09-28 江西彩石医薬科技有限公司 ピリドン誘導体と、その組成物、並びにそれらが抗ウイルス薬物としての応用
JP6590436B1 (ja) * 2018-04-24 2019-10-16 塩野義製薬株式会社 安定性に優れた固形製剤
AU2019259686B2 (en) 2018-04-24 2023-05-25 Shionogi & Co., Ltd. Solid formulation having excellent stability
WO2020058745A1 (en) * 2018-09-18 2020-03-26 Shionogi & Co., Ltd. Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof
EP3866778B1 (en) * 2018-10-17 2022-11-30 Cocrystal Pharma, Inc. Combinations of inhibitors of influenza virus replication
WO2020102270A1 (en) * 2018-11-13 2020-05-22 Cocrystal Pharma, Inc. Formulations of influenza therapeutics
CN111377944A (zh) * 2018-12-25 2020-07-07 广东东阳光药业有限公司 Baloxavir marboxil晶型及其制备方法
CN111410661B (zh) * 2019-01-04 2023-05-05 周雨恬 帽依赖性内切核酸酶抑制剂及其用途
WO2020177715A1 (zh) * 2019-03-05 2020-09-10 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
MX2021010884A (es) 2019-03-12 2022-01-19 Shionogi & Co Tratamiento de la influenza con derivados de piridona policiclica sustituida y profarmacos de los mismos en un sujeto que tiene influenza y factor de riesgo de complicacion.
WO2020194024A1 (en) * 2019-03-22 2020-10-01 Shionogi & Co., Ltd. Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a severe influenza condition
US20220008429A2 (en) * 2019-03-22 2022-01-13 Shionogi & Co., Ltd. Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a severe influenza condition
CN113924147A (zh) * 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
EP3714889A1 (en) 2019-03-29 2020-09-30 F. Hoffmann-La Roche AG Baloxavir for the prevention of transmission of influenza virus
CN111825699B (zh) * 2019-04-15 2023-02-21 上海复星星泰医药科技有限公司 含硫杂环化合物及其制备方法
CA3142030A1 (en) * 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Compounds useful to treat influenza virus infections
US20210069204A1 (en) * 2019-08-13 2021-03-11 F. Hoffmann-La Roche Ag Dosage of baloxavir marboxil for pediatric patients
WO2021038480A1 (en) * 2019-08-27 2021-03-04 Janssen Pharmaceuticals, Inc. Combinations for treating influenza virus
WO2021093860A1 (zh) * 2019-11-13 2021-05-20 南京知和医药科技有限公司 取代的双三环化合物及其药物组合物和用途
CN112920202A (zh) * 2019-12-05 2021-06-08 北京凯因科技股份有限公司 一种帽依赖性蛋白酶抑制剂
CN113045589A (zh) * 2019-12-27 2021-06-29 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN112898346B (zh) * 2020-01-23 2023-11-10 南京知和医药科技有限公司 水溶性多环化合物及其药物组合物和用途
EP4093440A1 (en) 2020-01-24 2022-11-30 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
CN111233891B (zh) * 2020-03-04 2021-05-04 江苏柯菲平医药股份有限公司 一种稠环吡啶酮衍生物及其制备方法和用途
CN115244049A (zh) * 2020-03-06 2022-10-25 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
CN112578034B (zh) * 2020-11-04 2022-02-11 广东众生睿创生物科技有限公司 一种手性胺小分子及其盐的质量控制方法
CN116783167A (zh) 2020-11-17 2023-09-19 盐野义制药株式会社 新颖吖啶鎓盐及其制造方法
CN114315827A (zh) * 2020-12-28 2022-04-12 维眸生物科技（上海）有限公司 多环吡啶并哒嗪酰胺并含肟碳环衍生物及其用途
TW202241430A (zh) * 2020-12-28 2022-11-01 日商塩野義製藥股份有限公司 包含dp1拮抗劑及神經胺酸酶抑制劑之病毒性呼吸道感染症治療用醫藥
TW202241431A (zh) * 2020-12-28 2022-11-01 日商塩野義製藥股份有限公司 包含dp1拮抗劑及帽依賴性核酸內切酶抑制劑之病毒性呼吸道感染症治療用醫藥
TW202308646A (zh) * 2021-05-10 2023-03-01 大陸商南京征祥醫藥有限公司 治療流感化合物的晶型及應用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2280435A (en) 1993-07-29 1995-02-01 Merck & Co Inc Anti-viral agent
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CA2634499A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
TW200800988A (en) 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
CN101610772B (zh) * 2007-02-16 2013-01-16 富山化学工业株式会社 包含吡嗪衍生物的药物组合物和使用吡嗪衍生物的联合用药的方法
HUE038837T2 (hu) 2009-06-15 2018-11-28 Shionogi & Co Helyettesített policiklusos karbamoilpiridon-származék
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
KR101773226B1 (ko) * 2010-09-24 2017-09-12 시오노기세야쿠 가부시키가이샤 치환된 다환성 카르바모일 피리돈 유도체의 프로드러그
US8859290B2 (en) 2011-07-22 2014-10-14 Rutgers, The State University Of New Jersey Inhibitors of influenza endonuclease activity and tools for their discovery
US20130102600A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
CA2874250A1 (en) 2012-05-23 2013-11-28 European Molecular Biology Laboratory 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
KR20150014506A (ko) 2012-05-23 2015-02-06 사피라 파르마슈티칼즈 게엠베하 바이러스성 질환의 치료, 개선 또는 예방에서 유용한 7-옥소-4,7-디하이드로-피라졸로[1,5-a]피리미딘 유도체
US8921388B2 (en) 2012-08-06 2014-12-30 European Molecular Biology Laboratory Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2014043252A2 (en) 2012-09-11 2014-03-20 Rutgers, The State University Of New Jersey Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones
US9701638B2 (en) 2012-11-09 2017-07-11 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
MX2015008292A (es) * 2013-01-08 2016-06-02 Savira Pharmaceuticals Gmbh Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
SG11201503946UA (en) 2013-01-08 2015-09-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
KR20150103034A (ko) 2013-01-08 2015-09-09 사피라 파르마슈티칼즈 게엠베하 피리돈 유도체 및 바이러스 질환의 치료, 개선 또는 예방에서의 이의 용도
CN105722831B (zh) 2013-09-12 2019-08-06 艾丽奥斯生物制药有限公司 哒嗪酮化合物及其用途
US9328119B2 (en) 2013-09-12 2016-05-03 Alios Biopharma, Inc. AZA-pyridone compounds and uses thereof
JP2017521423A (ja) 2014-07-07 2017-08-03 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ピリドピラジン化合物及びインフルエンザの治療、改善又は予防におけるそれらの使用
CN107074880A (zh) 2014-07-07 2017-08-18 萨维拉制药有限公司 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
JP5971830B1 (ja) * 2015-04-28 2016-08-17 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグ
PL3428170T3 (pl) * 2015-04-28 2021-05-31 Shionogi & Co., Ltd Pochodna policyklicznego pirydonu o działaniu przeciwgrypowym i jej prolek
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
WO2017072341A1 (en) 2015-10-30 2017-05-04 F. Hoffmann-La Roche Ag Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6806413B2 (ja) 2016-02-03 2021-01-06 塩野義製薬株式会社 多環性ピリドン誘導体およびそのプロドラッグ
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX2018016267A (es) 2016-06-20 2019-05-20 Shionogi & Co Metodo para producir derivado de piridona policiclica sustituida y cristal del mismo.
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
CA3033180C (en) * 2016-08-10 2022-05-31 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
CN108218873B (zh) 2016-12-15 2020-07-07 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN108727369B (zh) 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN108440564B (zh) 2018-04-11 2019-08-06 安帝康（无锡）生物科技有限公司 被取代的多环氨基甲酰基吡啶酮衍生物及其前药

Also Published As

Publication number Publication date
EP3391888C0 (en) 2023-09-27
ZA201803246B (en) 2019-07-31
HK1254961A1 (zh) 2019-08-02
SG10201911957QA (en) 2020-02-27
IL260025A (en) 2018-07-31
JPWO2017104691A1 (ja) 2018-04-05
BR112018011103A2 (pt) 2018-11-21
US20200261481A1 (en) 2020-08-20
US11040048B2 (en) 2021-06-22
MX2018006966A (es) 2018-09-21
CR20180356A (es) 2018-08-22
EP3391888A4 (en) 2019-07-03
WO2017104691A1 (ja) 2017-06-22
SG11201804348SA (en) 2018-06-28
EP3391888A1 (en) 2018-10-24
AU2016374416A1 (en) 2018-06-14
KR102084109B1 (ko) 2020-03-03
MA44080A (fr) 2018-10-24
JP6323860B2 (ja) 2018-05-16
CN108697715A (zh) 2018-10-23
RU2018121145A (ru) 2020-01-17
CL2018001618A1 (es) 2018-12-21
RU2745071C2 (ru) 2021-03-18
KR20180080320A (ko) 2018-07-11
CA3008607A1 (en) 2017-06-22
EP3391888B1 (en) 2023-09-27
RU2018121145A3 (es) 2020-03-06

Similar Documents

Publication Publication Date Title
PE20181516A1 (es) Medicamento para tratar la gripe caracterizado por combinar un inhibidor de endonucleasa dependiente de cap y un farmaco antigripal
CL2017002711A1 (es) Derivados de piridona policíclica sustituida y profármaco de los mismos
CR20190123A (es) Composiciones farmacéuticas que contienen derivados de piridona policíclicos sustituídos y profármacos de los mismos
UY36308A (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
CO2017005992A2 (es) Compuestos de triazolopirimidina y usos de los mismos
CY1123200T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια διαταραχων του κνς
CL2016003293A1 (es) Inhibidores de mnk y método relacionado al mismo
CO2017000222A2 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
NI201600101A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY36212A (es) Moduladores de receptores tipo toll para el tratamiento del vih
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
MY189144A (en) Substituted polycyclic pyridone derivatives and prodrugs thereof
AR103680A1 (es) Inhibidores selectivos de bace1
UY36123A (es) Derivados de carboxamida
SV2016005313A (es) Derivados de carboxamida
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CL2017000662A1 (es) Inhibidores de la histona desmetilasa.
ECSP18056196A (es) Derivados de indano
CU20160170A7 (es) Derivados de carboxamida
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico
UY36096A (es) Inhibir el canal de iones del potencial del receptor transitorio a1